Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Repligen Corporation Common Stock — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.73 (market cap $44.60B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 4× Repligen Corporation Common Stock's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is more actively traded (3,957,816 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 67 Days and Repligen Corporation Common Stock for 0 Days on average.
| JEPQ | RGEN | |
|---|---|---|
Market Cap | $44.60B | $11.14B |
Volume | 3,957,816 | 1,259,263 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $194.57 |
52-Week Low | $53.77 | $102.87 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.92, showing minimal daily movement with a neutral technical signal. The ETF maintains a covered-call strategy focused on Nasdaq exposure, generating monthly income through dividends. Recent distributions have shown variability, with payouts ranging from $0.57 to $0.70 per share. Moving averages indicate bullish momentum while oscillators remain neutral, suggesting balanced near-term positioning.
The ETF offers high-yield income potential with an estimated 11% annualized yield, though price appreciation may be limited by the covered-call strategy. Key risks include market volatility dependence and potential tax implications from return of capital. Institutional interest remains strong, with recent acquisitions signaling confidence in the income strategy.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
